Interview with Nihal Aygun, CEO, Corena Turkey
Mrs Aygun, could you please introduce yourself to our readers and give us an overview of CORENA? I have an educational background in chemistry and a professional experience in several…
UCB, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system in Belgium and internationally. The company’s core products include Cimzia for Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis; Vimpat for the treatment of epilepsy partial-onset seizures (POS); and Neupro for Parkinson’s disease and restless legs syndrome. It also offers Keppra for epilepsy POS, epilepsy primary generalized tonic-clonic seizures (PGTCS), and epilepsy myoclonic seizures; Zyrtec and Xyzal for allergy; Metadate for attention deficit and hyperactivity disorders; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for narcolepsy with cataplexy in adult patients. In addition, the company provides Tussionex for relief of cough and upper respiratory symptoms associated with allergy or a cold; and Lortab for the relief from pain. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.
UCB products have been on the Turkish market since 1960, through the Turkish distributor Bilim. After 30 years, UCB Turkey was founded in 1990 with operations beginning in 1992.
Contact Details
Palladium Tower, Barbaros Mah.
Kardelen Sokak , No:2 Kat:24/80
34746 Ataşehir, İstanbul
Tel: +90 216 538 0000
Fax: +90 216 538 0009
E-mail: tr-bilgi@ucb.com
Website: www.ucb.com.tr
Mrs Aygun, could you please introduce yourself to our readers and give us an overview of CORENA? I have an educational background in chemistry and a professional experience in several…
You are among the youngest GM’s of the top 200 companies in Turkey. What factors would you attribute to the rapid advancement of your career? I would say that there…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Mr Yusuf, Pharmaceutical Executive’s readers are keen to discover, through our reports, prominent industry personalities, and they like to hear their stories. Having been instrumental in the formation of the…
IEIS is an association with dual responsibilities. Promotion of generic usage in turkey and ensuring the sustained development of a local manufacturing industry. Before we look into these two aspects,…
Even though you have delivered strong results in most of the markets you have been appointed, this is your first assignment as the head of a subsidiary. For a man…
We are here with a very young company, created in 2009, so only three years old. As you mentioned before the interview, you first started to work in the medical…
Before we start with the interview I noticed that previously you were in charge of other regions aside from turkey. Is that still the case? If not why did IMS…
Mr Sözeri, Pharmaceutical Executive’s readers are keen to discover, through our reports, prominent industry personalities, and they like to hear their stories. You have an outstanding career, having worked for…
Could you introduce the organisation and its objectives to our readers? The International Investors Association of Turkey (YASED) is a non-governmental organization whose members are international companies operating in Turkey.…
Turkey remains a country between two worlds. Not only is it straddled between Asia and Europe, it also boasts a very strong and modern “western” industry and infrastructure together with…
See our Cookie Privacy Policy Here